|
Patritumab deruxtecan Clinical Trials
9 actively recruiting trials across 6 locations
Also known as: HER3-DXd, MK-1022, U3-1402
Pipeline
Phase 2: 2Phase 3: 1Phase 1/2: 6
Top Sponsors
- Merck Sharp & Dohme LLC7
- Samsung Medical Center1
- Gustave Roussy, Cancer Campus, Grand Paris1
Indications
- Cancer9
- Breast Cancer4
- Breast Neoplasms3
- Gastroesophageal Junction1
- Gastroesophageal Adenocarcinoma1
Other2 trials
Santa Monica, California2 trials
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
UCLA Hematology/Oncology - Parkside ( Site 0021)
Phase 2
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
UCLA Hematology Oncology Santa Monica ( Site 1205)
Phase 1/2
Daphne, Alabama1 trial
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Southern Cancer Center (SCC) ( Site 8000)
Phase 3
Tucson, Arizona1 trial
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)
Phase 1/2
Los Angeles, California1 trial
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Childrens Hospital Los Angeles ( Site 3006)
Phase 1/2
Clermont, Florida1 trial
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Clermont Oncology Center ( Site 0041)
Phase 1/2
Boston, Massachusetts1 trial
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Dana-Farber Cancer Institute ( Site 0050)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.